Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
ORLANDO, FL / ACCESSWIRE / April 1, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pharmaceutical company with a specific focus on transdermal technologies, today announces it has been engaged by and received a first order from Fit For Life Group (FFL), a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer.
佛羅里達州奧蘭多/ACCESSWIRE/2024年4月1日/專門專注於透皮技術的製藥公司Nutriband Inc.（納斯達克股票代碼：NTRB）（納斯達克股票代碼：NTRBW）今天宣佈，它已受主要品牌許可持有者Fit For Life Group（FFL）的聘用並獲得了第一筆訂單。預計隨後將簽署一份全面執行的供應商協議。Nutriband Inc. '其全資合同製造子公司Active Intelligence將充當製造商。
Founded in 2016, Fit for Life Group has become a market leader for fitness equipment and yoga accessories. FFL has amassed an impressive portfolio of brands including Gaiam, Reebok, Adidas, New Balance, SPRI and FILA. FFL is committed to creating innovative products for everyone, from beginners to pros. FFL's distribution and retail partners include larger national retailers such as Target, Walmart, Dick's Sporting Goods and Amazon.
Fit for Life集團成立於2016年，現已成爲健身器材和瑜伽配件的市場領導者。FFL已經積累了大量令人印象深刻的品牌組合，包括蓋亞姆、銳步、阿迪達斯、新百倫、SPRI和FILA。FFL 致力於爲從初學者到專業人士的所有人創造創新產品。FFL的分銷和零售合作伙伴包括大型全國性零售商，例如塔吉特、沃爾瑪、迪克體育用品和亞馬遜。
"This purchase order from FFL allows Nutriband and our contract manufacturing subsidiary, Active Intelligence, to once again demonstrate our capabilities in the development and manufacturing of innovative products. We are excited to continue to showcase Active Intelligence's capabilities and innovation by partnering with some of the world's largest brands," said Gareth Sheridan, CEO of Nutriband.
“FFL的這份採購訂單使Nutriband和我們的合同製造子公司Active Intelligence能夠再次展示我們在開發和製造創新產品方面的能力。我們很高興通過與一些世界上最大的品牌合作，繼續展示Active Intelligence的能力和創新。” Nutriband首席執行官加雷斯·謝里丹說。
About Nutriband Inc.
關於 Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
我們主要從事透皮藥物產品組合的開發。我們正在開發的主要產品是含有我們的 AVERSA 濫用威懾技術的芬太尼貼劑。AVERSA技術可以集成到任何透皮貼劑中，以防止濫用、濫用、轉移和意外接觸可能濫用的藥物。
The Company's website is . Any material contained in or derived from the Company's websites, or any other website is not part of this press release.
該公司的網站是。本公司網站或任何其他網站中包含或衍生的任何材料均不屬於本新聞稿的一部分。
Forward-Looking Statements
前瞻性陳述
Certain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended Jan. 31, 2023, filed April 26, 2023, the Forms 10-Q's filed subsequent to the Form 10-K in 2023, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
本新聞稿中包含的某些聲明，包括但不限於包含 “相信”、“預期”、“期望” 等詞語的陳述以及類似含義的詞語，構成1995年《私人證券訴訟改革法》所指的 “前瞻性陳述”。此類前瞻性陳述涉及已知和未知的風險和不確定性。由於多種因素，公司的實際業績可能與其前瞻性陳述中的預期存在重大差異，包括公司開發其擬議的濫用威懾性芬太尼透皮系統和其他擬議產品的能力、爲其濫用技術獲得專利保護的能力、獲得開發產品和進行必要臨床測試所需的融資的能力、獲得聯邦食品藥品監督管理局批准以銷售任何產品的能力它可能開發的產品在美國並獲得在其他國家（包括歐洲國家）銷售任何產品所必需的任何其他監管批准；其銷售其可能開發的任何產品的能力；創造、維持、管理和預測其增長的能力；吸引和留住關鍵人員的能力；公司業務戰略或發展計劃的變化；競爭；業務中斷；負面宣傳以及國際、國家和地方總體經濟和市場狀況以及通常與資本不足相關的風險化的發展中公司，以及該公司於2023年4月26日提交的S-1表格、截至2023年1月31日止年度的10-K表格、繼2023年10-K表格之後提交的10-Q表以及公司向美國證券交易委員會提交的其他文件中 “風險因素” 和 “管理層對財務狀況和經營業績的討論和分析” 中包含的風險。除非適用法律要求，否則我們沒有義務修改或更新任何前瞻性陳述以反映本聲明發布之日之後可能發生的任何事件或情況。
For more information, contact:
欲了解更多信息，請聯繫：
RedChip
Email: Info@redchip.com
Phone: 1-800-REDCHIP (733-2447)
Address:
431 E Horatio Ave, Suite #100,
Maitland, FL 32751
RedChip
電子郵件：Info@redchip.com
電話：1-800-REDCHIP (733-2447)
地址：
霍雷肖大道東431號，#100 套房，
佛羅里達州梅特蘭 32751
Nutriband Inc.
Phone: 407-377-6695
Email: Support@nutriband.com
Nutriband Inc.
電話：407-377-6695
電子郵件：Support@nutriband.com
SOURCE: Nutriband Inc.
來源：Nutriband Inc.
譯文內容由第三人軟體翻譯。